All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 8, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory front

May 25, 2018
No Comments
Drug prices were part of the conversation Wednesday as delegates to the 71st World Health Assembly asked the World Health Organization (WHO) to elaborate on a five-year roadmap to address the global shortage of, and access to, medicines and vaccines that's to be presented at next year's assembly. 
Read More

Week in review

March 12, 2018
No Comments

CEPI betting up to $37.5M on Themis for Lassa, MERS vaccines

March 7, 2018
By Cormac Sheridan
No Comments
DUBLIN – The Coalition for Epidemic Preparedness Innovations (CEPI), an international public-private partnership raising $1 billion to incentivize the development of vaccines for neglected infectious diseases, has made its first big bet – a contract, worth up to $37.5 million, with Themis Bioscience GmbH to develop vaccines against Lassa virus and Middle East respiratory syndrome-related coronavirus (MERS-CoV).
Read More

Epidemics come and go, but surprise is forever

March 6, 2018
By Anette Breindl
No Comments
BOSTON – Has biomedicine learned from the HIV epidemic? Yes and no. Certainly, Biomedicine has learned how to deal with HIV.
Read More

Regulatory front

Feb. 5, 2018
No Comments

Bench Press: BioWorld looks at translational medicine

Jan. 22, 2018
No Comments
Metastases cause a large majority of cancer deaths, and understanding their mechanisms might offer therapeutic opportunities. A team from Case Western Reserve University investigated a possible role of enhancers, regulatory DNA elements that can influence the transcription of downstream genes.
Read More

Bench Press: BioWorld looks at translational medicine

Aug. 7, 2017
By Anette Breindl
No Comments
Activating mutations in the BRAF kinase, such as those targeted by melanoma drug Zelboraf (vemurafenib, Roche Holding AG), are a well-known cause of cancer.
Read More

Bench Press: BioWorld looks at translational medicine

July 3, 2017
By Anette Breindl
No Comments
Researchers from the International Mouse Phenotypic Consortium have published the comprehensive phenotypes of more than 3,300 knockout mice, describing mouse models for 360 diseases.
Read More

New $1B coalition aims to be vaccine-ready for potential outbreaks

Jan. 19, 2017
By Nuala Moran
No Comments
LONDON – A $1 billion program to develop vaccines against emerging infectious diseases that, like Zika and Ebola viruses, have the potential to cause serious epidemics, will be launched at the World Economic Forum in Davos, Switzerland.
Read More

Bench Press: BioWorld looks at translational medicine

Dec. 5, 2016
By Anette Breindl
No Comments
Mitochondrial DNA with mutations was sometimes preferentially replicated after spindle transfer to donor eggs, with the end result that the mutated mitochondria were once again dominant after transplantation.
Read More
Previous 1 2 … 494 495 496 497 498 499 500 501 502 … 511 512 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 8, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • Gavel and First Amendment

    Citing US constitutional violations, Merck the first to challenge the IRA

    BioWorld
    The question wasn’t if, but when and how, someone would challenge the Medicare negotiation provision laid out in the Inflation Reduction Act (IRA) that was signed...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing